Proteona enters EIT-Health Amgen challenge on multiple myeloma treatment strategy
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Proteona is honoured to be part of the 2020 Startups Meet Pharma program by EIT-Health. Proteona will join three other startups for the Amgen challenge: Choosing the right treatment for Multiple Myeloma patients.
“We are excited to work alongside Amgen, who developed multiple effective solutions for difficult and relapsing multiple myeloma,” Said Dr Andreas Schmidt, CEO of Proteona. “Relapse is unfortunately common in multiple myeloma, and a precision medicine tool is badly needed. Each patient has a unique cancer makeup and response. There are many possible options but no objective way to guide decision-making.”
Proteona addresses the problem by building a single cell proteogenomic database of multiple myeloma drug response. For each sample, protein and gene expression patterns will be analysed in thousands of single cells, providing rich information on cancer heterogeneity, mechanisms of drug resistance, and potential treatment targets. Proteona then uses AI-assisted algorithms to mine the complex data to discover patterns that can guide future treatment. Proteona is presenting its scientific progress on multiple myeloma at the upcoming EHA annual congress.
The technology is based on Proteona’s ESCAPE™ platform, which uses DNA-barcoded antibodies to capture protein expression information in addition to mRNA expression data from single cells.
To protect multiple myeloma patients and other individuals with immunocompromised conditions in the current pandemic. Proteona is leading an international alliance to develop neutralizing antibody against COVID-19.
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.